Choose your language
Skip to article content

NEW TO PEPTIDES? START HERE

Peptide and hormone
research library.

Peptides are short chains of amino acids, the building blocks also used in proteins. Different peptides have different roles and evidence. Start with the basics, or explore familiar GLP names such as Ozempic and Reta below.

Peptide definition · NIH / NHGRI ↗
8 topic guides40 linked sourcesPlain-language study context

YOUR FIRST GUIDE

What is a peptide?

Learn how amino acids form peptides, why some act as signals and why the word “peptide” is not evidence of a shared health benefit.

Watch & learn the basics
Peptide basics · Start here

RESEARCH LIBRARY

Find your starting point.

Browse by interest. Categories describe research topics, not promised benefits. Each guide keeps the study context, sources and evidence limits together.

8 of 8 published guides

EXPLORE THE TOPIC

Start Here: Peptide Basics

Understand the building blocks, then learn how to read a study.

EXPLORE THE TOPIC

GLP Family & Weight-Management Research

Connect familiar names with compound names, receptor targets and trial evidence.

KNOW A NAME LIKE OZEMPIC?

Start with the name.
Then understand the difference.

A brand name, a compound name and a receptor target describe different things. These examples help connect the terms.

Prescription brands

Semaglutide

Ozempic · Wegovy

Receptor targets
GLP-1

Ozempic and Wegovy are brand names for medicines containing semaglutide. Semaglutide activates GLP-1 receptors; each medicine has its own approved uses and formulation.

NIH medicine-name reference ↗

Prescription brands

Tirzepatide

Mounjaro · Zepbound

Receptor targets
GIP + GLP-1

Mounjaro and Zepbound contain tirzepatide. It activates two receptor types, GIP and GLP-1, and is a different compound from semaglutide.

NIH medicine-name reference ↗

Investigational · Phase 3

Retatrutide

Often called “Reta”

Receptor targets
GIP + GLP-1 + glucagon

Reta is a newer compound in weight-management research. It activates three receptor types and remains investigational, without FDA approval. More receptor targets do not establish that it is the best choice.

Developer status & mechanism ↗
What does the retatrutide weight-loss evidence show?

TRIUMPH-1 randomized 2,339 adults with obesity without diabetes to retatrutide or placebo for 80 weeks. In its treatment-regimen analysis, the highest-dose group averaged 25.0% weight reduction versus 3.9% with placebo. Gastrointestinal adverse events were most common.

This was a comparison with placebo, not Ozempic or tirzepatide. It does not establish a universal “best for weight loss” choice. Different analyses can produce different estimates; the guide explains the trial headlines and their limits.

Read the peer-reviewed Phase 3 trial abstract ↗ · Explore the retatrutide guide →

What about names such as “GLP-3”?

“GLP-3” is informal shorthand, not a recognized scientific class. Retatrutide is described scientifically as a triple receptor agonist. A higher number in an informal name is not evidence that a compound is better.

Read the developer’s explanation ↗

These are educational comparisons of medicines and studied compounds. They do not establish that a GreysProtocol retail item is equivalent to a prescription medicine or the material used in a trial. FDA context ↗

Primary sources checked October 31, 2026. Retatrutide status can change; consult the linked source for updates.

EXPLORE THE TOPIC

Growth Hormone & Related Compounds

Explore hormone physiology and distinguish biological mechanisms from measured outcomes.

EXPLORE THE TOPIC

Recovery & Tissue Research

Read the tissue and nerve research questions, with personal accounts separated from study findings.

EXPLORE THE TOPIC

Skin & Tissue Research

Start with copper-peptide chemistry and what cell-culture studies can tell us.

EXPLORE THE TOPIC

Energy & Metabolism

Explore mitochondrial signals and the difference between laboratory findings and exercise measurements.

EXPLORE THE TOPIC

Brain & Nervous-System Research

Explore brain-cell and peripheral-nerve questions, with the evidence type made clear.

HOW THESE GUIDES ARE PREPARED

How we review the research.

See how sources are selected, how laboratory, animal and human evidence are separated, how videos are checked against their guides, and why widespread real-world use is not the same as a clinical study.

Read our research standards

READ WITH CONTEXT

Three questions for every study.

Explore the illustrated guide to cells, animal models and human studies ↗

Who or what was studied?

Cells, animals and people provide different evidence. A finding in one model does not automatically apply to another.

What was measured?

A biological marker, a physical measurement and an improvement in symptoms are different outcomes.

What remains uncertain?

Read the comparison, study size and follow-up alongside the finding. An explanation of a mechanism is not a treatment recommendation.